Navigation Links
Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
Date:9/11/2011

ultiple proprietary siRNA delivery technology platforms including AtuPLEX™ and DACC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the second half of 2011.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

About InteRNA Technologies B.V. (http://www.interna-technologies.com'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
2. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
3. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
4. Silence Therapeutics Provides Year-end Update
5. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
6. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
7. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Silence Therapeutics Announces Board Changes
10. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
11. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... separating membrane market has witnessed robust development with the growth ... a later starter. In 2012, the size of ... with the proportion worldwide soaring to 16.3%. It is projected ... continue its growth rate by around 20% in the upcoming ... roughly RMB25 billion. An integrated membrane industrial system ...
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... TORONTO, Dec. 20, 2011  Generex Biotechnology Corporation (OTCBB: GNBT.OB) ... the Antigen Express breast cancer vaccine did not ... Bloomberg Television,s December 16, 2011 promotional spot).  The ... of Bloomberg Television advise as to a rescheduled ...
... Pharma Corporation (OTCBB: NPHC), a biotechnology company that is ... (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the ... a Shareholder Letter on the Company,s website. ... explained Rik J. Deitsch, Chairman and CEO of ...
Cached Medicine Technology:Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment 2Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment 3Nutra Pharma Letter to Shareholders 2
(Date:12/21/2014)... Theme and plugin developers ... plugin for Final Cut Pro X entitled ProMotion. , ... more with absolute ease.” Said Christiana Austin, CEO of ... needed to easily animate their media inside FCPX.” , ... users to animate pictures, videos, logos, and more with ...
(Date:12/20/2014)... BambooIndustry.com is a professional company ... business has recently shown its new engineered bamboo flooring ... bamboo flooring models. , BambooIndustry.com’s customers come from many ... more. According to the CEO of the company, the ... in the past few years, and the demand for ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its ... Christmas Sale, offering big discounts on all of its special ... idea to own a perfect wedding gown. If you have ... then come to LunaDress. Many different wedding dress styles and ... website now and enjoy the current special offer, up to ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The Doctor’s Office ... for the better part of a decade. They’ve treated ... a better, faster healthcare alternative to the Paramus ... announce three new additions to their staff of top-notch board ... Jill Zeiger MD. These new doctors will work ...
(Date:12/20/2014)... December 20, 2014 Recently, AngelWeddingDress.com has ... Discount ”) for the coming Christmas. In the promotion, ... 80% off. , “We have something special for the ... the holiday season. Moreover, our new collections of 2015 ... are offered now at greatly discounted prices. Visit our ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... recent report in Nature Medicine had said that the ... Encephalitis in India is due to lack of preparedness ... early vaccination programs//. The encephalitis infection is spread by ... in water logged paddy fields in the monsoon seasons. ...
... in the July issue of the journal Environmental Health ... levels and age of onset of natural menopause//. ... to reflect the rate of atrophy of the ovarian ... health implications because women with early menopause are at ...
... for its miraculous properties, Herceptin, the breast cancer wonder ... British medical journal questioned its effectiveness//. ,"The ... is profoundly misleading to suggest, even rhetorically, that the ... breast cancer," the editors of The Lancet wrote in ...
... role in female mortality, second only to infanticide in Asian ... student of economics at Harvard University//, found that infanticide may ... to female ratios in many Asian countries, reports science portal ... particularly China, where some 10 to 15 percent of the ...
... a multinational company to bring a cost effective vaccine ... Minister Anbumani Ramadoss //on the occasion of National Cancer ... cancer has been instrumental behind the initiative. ... mobilizing things to implement the plan in association with ...
... that reflecting on personal values can keep neuroendocrine and ... is implicated in the development //and progression of a ... and research on the self suggest that self-affirming activities ... study, published in the November issue of the journal ...
Cached Medicine News:Health News:Herceptin Not A ‘Wonder’ Drug, Says The Lanc 2Health News:Cervical Cancer Vaccine To Be Developed In India 2
... from monofilament polypropylene, is used for hernia ... wall. The monofilaments are knitted into an ... is characterized by the extreme dimensional stabilityof ... to movements of the patient. ,The technically ...
... of the Applied Fiberoptics headlight delivers a ... six models to choose from, with both ... ranges from 15 mm to 120 mm., ... with any of our quality fiberoptic cables ...
... Orion incorporates superior optics in a durable ... fully adjustable headband, made of white molded ... the brow, directing the spot along your ... the headband position the cable diagonally over ...
... seven pounds of intelligent Pulse Oximeter ... software developed over 7 years by ... ultimate in non-invasive oxygen saturation monitoring. ... technology and sophisticated saturation sensor designs ...
Medicine Products: